What is the current stock price of Graybug Vision, Inc. (GRAY)?

As of the latest market data, Graybug Vision, Inc. (GRAY) is trading at $5.50. The stock has seen a loss of -10.80% today.

Does Graybug Vision, Inc. (GRAY) pay a dividend?

Based on current data, Graybug Vision, Inc. does not have a confirmed active dividend policy.

What is the market cap of Graybug Vision, Inc.?

The current market capitalization of Graybug Vision, Inc. (GRAY) is approximately unavailable.

GRAY

Graybug Vision, Inc.·Healthcare

5.50

10.795%(−0.67)

Close Price

Last Updated: — ET

52W L: $4.8852W H: $20.30

GRAY NEWS

globenewswire.com

May 7

GRAY ANNOUNCES QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Gray Media, Inc. (“Gray”) (NYSE: GTN) announced today that its Board of Directors has authorized a quarterly cash dividend of $0.08 per share of its common stock and Class A common stock. The dividend is payable on June 30, 2026, to shareholders of record at the close of business on June 15, 2026.

globenewswire.com

May 6

Grayscale Investments® Announces Rebalancing of Multi-Asset Funds for First Quarter 2026

STAMFORD, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world's largest digital asset-focused investment platform*, and manager of Grayscale® Decentralized Finance (DeFi) Fund (OTCQB: DEFG) (DEFG Fund), and Grayscale® Smart Contract Fund (GSC Fund), today announced the updated Fund Component weightings for each product in connection with their respective first quarter 2026 reviews.

newsfilecorp.com

May 1

Graycliff Exploration Announces New CFO and Independent Director

Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Graycliff Exploration Limited (CSE: GRAY) (OTC Pink: GRYCF) (FSE : GE0) (the "Company" or "Graycliff") is pleased to announce that further to his role as a director of the Company, Jason Baker has been appointed Chief Financial Officer ("CFO"), replacing Julio DiGirolamo, who has also resigned as director. Mr. Baker is a finance professional with Altus Capital Partners, a boutique investment bank based in Vancouver, B.C.

defenseworld.net

Apr 25

Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)

Insider and Institutional Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money

newsfilecorp.com

Apr 8

Graycliff Exploration Closes Oversubscribed Private Placement

Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Graycliff Exploration Limited (CSE: GRAY) (OTC Pink: GRYCF) (FSE: GE0) (the "Company" or "Graycliff") is pleased to announce that it closed its previously announced private placement (the "Offering"). The Company raised gross proceeds of $650,000 via the issuance of 5,416,308 common share units of the Company ("Units").

globenewswire.com

Apr 7

GRAY SETS DATE FOR FIRST QUARTER EARNINGS RELEASE AND EARNINGS CONFERENCE CALL

ATLANTA, April 07, 2026 (GLOBE NEWSWIRE) -- Gray Media, Inc. (NYSE: GTN) today announced that it will release its earnings results for the quarter ended March 31, 2026, on Thursday, May 7, 2026.

Company Profile

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-09-04

Beta

1.20

Websitewww.graybug.vision↗